Medicine:COVI-VAC
From HandWiki
Short description: Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | Attenuated virus |
| Clinical data | |
| Trade names | CDX-005[1] |
| Routes of administration | Intranasal |
COVI-VAC (codenamed CDX-005) is a COVID-19 vaccine developed by Codagenix, Inc.[2] It is a live attenuated vaccine administered intranasally and requires just one dose. It is currently in Phase 1 clinical trials, involving 48 participants which runs from December 2020 to June 2021.[3][4]
References
- ↑ "Serum Institute starts manufacturing Codagenix's nasal COVID-19 vaccine" (in en). mint. 22 September 2020. https://www.livemint.com/science/health/serum-institute-of-india-starts-manufacturing-codagenix-s-nasal-covid-19-vaccine-11600779086792.html.
- ↑ "COVI-VAC for SARS-CoV-2 (COVID-19)". Codagenix, Inc.. https://codagenix.com/vaccine-programs/covid-19/.
- ↑ "Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19". United States National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT04619628.
- ↑ "Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy". Proceedings of the National Academy of Sciences of the United States of America 118 (29). July 2021. doi:10.1073/pnas.2102775118. PMID 34193524.
 |
